Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adma Biologics
(NQ:
ADMA
)
9.425
+0.015 (+0.16%)
Streaming Delayed Price
Updated: 12:26 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adma Biologics
< Previous
1
2
Next >
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ET
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
March 11, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
March 05, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces CFO Transition
February 28, 2024
Executive Search Initiated for CFO Replacement
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 28, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
February 21, 2024
Conference Call Scheduled for February 28, 2024, at 4:30 p.m. ET
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
February 21, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
January 08, 2024
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
December 18, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
December 12, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
November 16, 2023
FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-Sufficiency
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023
November 01, 2023
Conference Call Scheduled for November 8, 2023, at 4:30 p.m. ET
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
August 09, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
August 02, 2023
Conference Call Scheduled for August 9, 2023, at 4:30 p.m. ET
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
July 19, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
May 03, 2023
Conference Call Scheduled for May 10, 2023, at 4:30 p.m. ET
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Amendment to Credit Agreement
May 02, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 23, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
March 16, 2023
Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
February 08, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
January 17, 2023
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®
December 13, 2022
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 09, 2022
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
December 07, 2022
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Proposed Public Offering of Common Stock
December 06, 2022
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
December 06, 2022
Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million
From
ADMA Biologics, Inc.
Via
GlobeNewswire
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
ADMA Biologics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.